Last reviewed · How we verify
Juvenile idiopathic arthritis
Approved treatments
- tumor necrosis factor inhibitors (TNFi) · Pfizer
- Abrilada · AbbVie
Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors. - Orencia · Bristol-Myers Squibb
Abatacept inhibits T-cell activation by binding CD80/CD86, blocking CD28 costimulatory interaction. - Humira · AbbVie
Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors. - TNF Inhibitor · Pfizer
- CYLTEZO · BOEHRINGER INGELHEIM
- Orencia · Bristol-Myers Squibb
- Simponi · Centocor Ortho Biotech Inc
Simponi works by binding to tumor necrosis factor, preventing it from interacting with its receptors and thereby reducing inflammation. - Roactemra · Roche
Roactemra works by blocking the interleukin-6 receptor, a protein that plays a key role in inflammation. - Infliximab [infliximab biosimilar 3] · Pfizer
Infliximab biosimilar 3 is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha) to treat inflammatory conditions. - tocilizumab or sarilumab · Pfizer
- Enbrel · Immunex
Enbrel works by binding to tumor necrosis factor, a protein that promotes inflammation, thereby reducing inflammation and alleviating symptoms. - Trexall · Generic (originally Lederle Laboratories)
Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune). - Methotrexat · Biocad
- Simponi · Alvotech Swiss AG
- Humira · Sohag University
- Enbrel · LG Life Sciences
Clinical guidelines
- FDA label — 1L|2L
Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. - FDA label — 1L|2L
Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Juvenile idiopathic arthritis patent landscape — cliff calendar, originator estates, attackable patents
- Juvenile idiopathic arthritis treatment landscape brief
- Juvenile idiopathic arthritis treatment updates RSS
Frequently asked questions about Juvenile idiopathic arthritis
What drugs treat Juvenile idiopathic arthritis?
Tracked treatments include tumor necrosis factor inhibitors (TNFi), Abrilada, Orencia, Humira, TNF Inhibitor, CYLTEZO, Simponi, Roactemra.
What is the treatment for Juvenile idiopathic arthritis?
Standard treatment for Juvenile idiopathic arthritis includes tumor necrosis factor inhibitors (TNFi), Abrilada, Orencia, Humira, TNF Inhibitor. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Juvenile idiopathic arthritis?
FDA label publishes guidelines for Juvenile idiopathic arthritis. 2 guideline references tracked.
Related
- Treatment landscape: Juvenile idiopathic arthritis patent cliff · Juvenile idiopathic arthritis CI report
- Treatment: tumor necrosis factor inhibitors (TNFi) · Pfizer
- Treatment: Abrilada · AbbVie
- Treatment: Orencia · Bristol-Myers Squibb
- Treatment: Humira · AbbVie
- Treatment: TNF Inhibitor · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing